Genetic Aspects of Age-Related Macular Degeneration and Their Therapeutic Potential
Open accessThe DOI matches its Crossref record; 174 of the 181 references it cites were found in a registry or an index.
Abstract
Age-related macular degeneration (AMD) is a complex and multifactorial disease, resulting from the interaction of environmental and genetic factors. The continuous discovery of associations between genetic polymorphisms and AMD gives reason for the pivotal role attributed to the genetic component to its development. In that light, genetic tests and polygenic scores have been created to predict the risk of development and response to therapy. Still, none of them have yet been validated. Furthermore, there is no evidence from a clinical trial that the determination of the individual genetic structure can improve treatment outcomes. In this comprehensive review, we summarize the polymorphisms of the main pathogenetic ways involved in AMD development to identify which of them constitutes a potential therapeutic target. As complement overactivation plays a major role, the modulation of targeted complement proteins seems to be a promising therapeutic approach. Herein, we summarize the complement-modulating molecules now undergoing clinical trials, enlightening those in an advanced phase of trial. Gene therapy is a potential innovative one-time treatment, and its relevance is quickly evolving in the field of retinal diseases. We describe the state of the art of gene therapies now undergoing clinical trials both in the field of complement-suppressors and that of anti-VEGF.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures

Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Genetic factors account for up to 70% of disease variability.”
From Genetics and Age-Related Macular Degeneration: A Practical Review for Clinicians. (2024) · cites this paper as [1]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Interestingly, most discovered variants are associated with all known AMD stages [1,17,24].”
From Genetics and Age-Related Macular Degeneration: A Practical Review for Clinicians. (2024) · cites this paper as [1]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Up to 70% of the clinical variability in AMD can be explained by genetic variants [1,17,20], meaning this disease may be amenable to personalized medical approaches.”
From Genetics and Age-Related Macular Degeneration: A Practical Review for Clinicians. (2024) · cites this paper as [1]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The ability to better riskstratify patients can improve outcomes by better allocating scarce resources to the patients most in need or by selecting the most effective treatment from alternatives [1,26].”
From Genetics and Age-Related Macular Degeneration: A Practical Review for Clinicians. (2024) · cites this paper as [1]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Other genes involving the complement cascade, lipid metabolism, extracellular matrix, and immune function have also been associated with AMD [1,17].”
From Genetics and Age-Related Macular Degeneration: A Practical Review for Clinicians. (2024) · cites this paper as [1]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Wong, W. L., Su, X., Li, X., Cheung, C. M. G., Klein, R., Cheng, C.-Y., & Wong, T. Y. (2014) · The Lancet Global Health · doi:10.1016/s2214-109x(13)70145-1 · Cited by 5,331 · cited 1×
“Age-related macular degeneration (AMD) has an estimated prevalence of 8% worldwide [1].”
BackgroundKhera, A. V., Chaffin, M., Aragam, K. G., Haas, M. E., Roselli, C., Choi, S. H., Natarajan, P., Lander, E. S., Lubitz, S. A., Ellinor, P. T., et al. (2018) · Nature Genetics · doi:10.1038/s41588-018-0183-z · Cited by 2,953 · cited 2×
“In the present review, we discuss the main genetic variants, focusing on molecules currently considered potential therapeutic targets that are now undergoing clinical trial [33,34].”
BackgroundComplement factor H polymorphism and age-related macular degeneration
Edwards, A. O., Ritter, R., Abel, K. J., Manning, A., Panhuysen, C., & Farrer, L. A. (2005) · Science · doi:10.1126/science.1110189 · Cited by 2,449 · cited 1×
“There is strong evidence that the rs1061170 CFH genetic variant tightly correlates to AMD [35,36] as it reduces the strength of the bond to heparan sulfate proteoglycans [58], causing lipoprotein deposition in Bruch’s membrane (BrM) and, consequently, drusen progression.”
BackgroundComplement factor H variant increases the risk of age-related macular degeneration
Haines, J. L., Hauser, M. A., Schmidt, S., Scott, W. K., Olson, L. M., Gallins, P., Spencer, K. L., Kwan, S. Y., Noureddine, M., Gilbert, J. R., et al. (2005) · Science · doi:10.1126/science.1110359 · Cited by 2,424 · cited 1×
“The mutation affects CFH in a region that binds C-reactive protein (CRP), a major marker of inflammation [59].”
BackgroundHageman, G. S., Anderson, D. H., Johnson, L. V., Hancox, L. S., Taiber, A. J., Hardisty, L. I., Hageman, J. L., Stockman, H. A., Borchardt, J. D., Gehrs, K. M., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0501536102 · Cited by 1,961 · cited 1×
“CFHI62V polymorphism is a protective haplotype [65].”
Fritsche, L. G., Igl, W., Bailey, J. N. C., Grassmann, F., Sengupta, S., Bragg-Gresham, J. L., Burdon, K. P., Hebbring, S. J., Wen, C., Gorski, M., et al. (2016) · Nature Genetics · doi:10.1038/ng.3448 · Cited by 1,544 · cited 5×
“The genetics of AMD is complex, involving 52 different variants in 34 genetic loci, according to the largest genome-wide association study ever conducted to date [33].”
BackgroundResultInfluentialHTRA1 Promoter Polymorphism in Wet Age-Related Macular Degeneration
DeWan, A., Liu, M., Hartman, S., Zhang, S. S.-M., Liu, D. T. L., Zhao, C., Tam, P. O. S., Chan, W. M., Lam, D. S. C., Snyder, M., et al. (2006) · Science · doi:10.1126/science.1133807 · Cited by 876 · cited 1×
“Other reports identified the regulatory region HTRA1 rs11200638 [50,51].”
BackgroundA Simplified Severity Scale for Age-Related Macular Degeneration: AREDS Report No. 18
(2005) · Archives of Ophthalmology · doi:10.1001/archopht.123.11.1570 · Cited by 807
The impact of oxidative stress and inflammation on RPE degeneration in non-neovascular AMD
Datta, S., Cano, M., Ebrahimi, K., Wang, L., & Handa, J. T. (2017) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2017.03.002 · Cited by 802 · cited 1×
“Moreover, the photo-oxidative stress produced by processing light for vision is a unique example of an additional source of stress [13].”
BackgroundDeveloping and evaluating polygenic risk prediction models for stratified disease prevention
Chatterjee, N., Shi, J., & García-Closas, M. (2016) · Nature Reviews Genetics · doi:10.1038/nrg.2016.27 · Cited by 697
Immunology of age-related macular degeneration
Ambati, J., Atkinson, J. P., & Gelfand, B. D. (2013) · Nature Reviews Immunology · doi:10.1038/nri3459 · Cited by 584 · cited 1×
“Overactivation of the complement pathway is a fundamental contributor to AMD pathogenesis [6].”
BackgroundAge-related macular degeneration
Coleman, H. R., Chan, C.-C., Ferris, F. L., & Chew, E. Y. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61759-6 · Cited by 542
Complement factor H binds malondialdehyde epitopes and protects from oxidative stress
Weismann, D., Hartvigsen, K., Lauer, N., Bennett, K. L., Scholl, H. P. N., Issa, P. C., Cano, M., Brandstätter, H., Tsimikas, S., Skerka, C., et al. (2011) · Nature · doi:10.1038/nature10449 · Cited by 533 · cited 1×
“This mechanism further links oxidative, lipid, and complement dysregulation in AMD [61].”
BackgroundLiao, D. S., Grossi, F. V., El Mehdi, D., Gerber, M. R., Brown, D. M., Heier, J. S., Wykoff, C. C., Singerman, L. J., Abraham, P., Grassmann, F., et al. (2020) · Ophthalmology · doi:10.1016/j.ophtha.2019.07.011 · Cited by 519
C5 Inhibitor Avacincaptad Pegol for Geographic Atrophy Due to Age-Related Macular Degeneration
Jaffe, G. J., Westby, K., Csaky, K. G., Monés, J., Pearlman, J. A., Patel, S. S., Joondeph, B. C., Randolph, J., Masonson, H., & Rezaei, K. A. (2021) · Ophthalmology · doi:10.1016/j.ophtha.2020.08.027 · Cited by 469
Kanda, A., Chen, W., Othman, M., Branham, K. E. H., Brooks, M., Khanna, R., He, S., Lyons, R., Abecasis, G. R., & Swaroop, A. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0703933104 · Cited by 441 · cited 1×
“The rs10490924/A69S polymorphism, which surrounds two genes, ARMS2 and HTRA1, has been reproducibly observed as a strong genetic risk factor for AMD [46,47].”
BackgroundVariation in complement factor 3 is associated with risk of age-related macular degeneration
Maller, J. B., Fagerness, J. A., Reynolds, R. C., Neale, B. M., Daly, M. J., & Seddon, J. M. (2007) · Nature Genetics · doi:10.1038/ng2131 · Cited by 437 · cited 1×
“The association between rs2230199 and rs1047286 in the C3 gene and AMD predisposition has been reported frequently [39,40].”
BackgroundAge-Related Macular Degeneration
Fine, S. L., Berger, J. W., Maguire, M. G., & Ho, A. C. (2000) · New England Journal of Medicine · doi:10.1056/nejm200002173420707 · Cited by 418
Risk factors for progression of age‐related macular degeneration
Heesterbeek, T. J., Lorés‐Motta, L., Hoyng, C. B., Lechanteur, Y. T. E., & den Hollander, A. I. (2020) · Ophthalmic and Physiological Optics · doi:10.1111/opo.12675 · Cited by 392 · cited 3×
“Another leading variant in CFH is rs10922109 [37].”
BackgroundInfluentialKeenan, T. D., & Chew, E. Y. (2017) · JAMA Ophthalmology · doi:10.1001/jamaophthalmol.2017.2210 · Cited by 377
Association between C-reactive protein and age-related macular degeneration
Seddon, J. M. (2004) · JAMA · doi:10.1001/jama.291.6.704 · Cited by 376
Systemic Complement Activation in Age-Related Macular Degeneration
Scholl, H. P. N., Issa, P. C., Walier, M., Janzer, S., Pollok-Kopp, B., Börncke, F., Fritsche, L. G., Chong, N. V., Fimmers, R., Wienker, T., et al. (2008) · PLoS ONE · doi:10.1371/journal.pone.0002593 · Cited by 363
Holz, F. G., Sadda, S. R., Busbee, B., Chew, E. Y., Mitchell, P., Tufail, A., Brittain, C., Ferrara, D., Gray, S., Honigberg, L., et al. (2018) · JAMA Ophthalmology · doi:10.1001/jamaophthalmol.2018.1544 · Cited by 354
Risk factors and biomarkers of age-related macular degeneration
Lambert, N. G., ElShelmani, H., Singh, M. K., Mansergh, F. C., Wride, M. A., Padilla, M., Keegan, D., Hogg, R. E., & Ambati, B. K. (2016) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2016.04.003 · Cited by 351
Seddon, J. M., Yu, Y., Miller, E. C., Reynolds, R., Tan, P. L., Gowrisankar, S., Goldstein, J. I., Triebwasser, M., Anderson, H. E., Zerbib, J., et al. (2013) · Nature Genetics · doi:10.1038/ng.2741 · Cited by 346 · cited 4×
“For instance, rare variants in CFI were reported to give reduced FI in serum [43,112].”
BackgroundInfluentialRivera, A., White, K., Stöhr, H., Steiner, K., Hemmrich, N., Grimm, T., Jurklies, B., Lorenz, B., Scholl, H. P. N., Apfelstedt-Sylla, E., et al. (2000) · The American Journal of Human Genetics · doi:10.1086/303090 · Cited by 338 · cited 1×
“G1961E and D2177N have been found associated to be with AMD [89], but still there are contradictions among studies [33,90].”
ResultMissense Variations in the Fibulin 5 Gene and Age-Related Macular Degeneration
Stone, E. M., Braun, T. A., Russell, S. R., Kuehn, M. H., Lotery, A. J., Moore, P. A., Eastman, C. G., Casavant, T. L., & Sheffield, V. C. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040833 · Cited by 324
A rare penetrant mutation in CFH confers high risk of age-related macular degeneration
Raychaudhuri, S., Iartchouk, O., Chin, K., Tan, P. L., Tai, A. K., Ripke, S., Gowrisankar, S., Vemuri, S., Montgomery, K., Yu, Y., et al. (2011) · Nature Genetics · doi:10.1038/ng.976 · Cited by 323
Further Evidence for an Association of ABCR Alleles with Age-Related Macular Degeneration
Allikmets, R. (2000) · The American Journal of Human Genetics · doi:10.1086/303018 · Cited by 303
Yehoshua, Z., Alexandre de Amorim Garcia Filho, C., Nunes, R. P., Gregori, G., Penha, F. M., Moshfeghi, A. A., Zhang, K., Sadda, S., Feuer, W., & Rosenfeld, P. J. (2014) · Ophthalmology · doi:10.1016/j.ophtha.2013.09.044 · Cited by 299
Reynolds, R., Hartnett, M. E., Atkinson, J. P., Giclas, P. C., Rosner, B., & Seddon, J. M. (2009) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.09-3928 · Cited by 294
Souied, E. H., Benlian, P., Amouyel, P., Feingold, J., Lagarde, J.-P., Munnich, A., Kaplan, J., Coscas, G., & Soubrane, G. (1998) · American Journal of Ophthalmology · doi:10.1016/s0002-9394(99)80146-9 · Cited by 292 · cited 1×
“It is well documented that the ε2 allele of ApoE correlates with a higher risk of advanced AMD, while ε4 has a protective role for wet AMD [86,87].”
BackgroundHahn, P. (2003) · Archives of Ophthalmology · doi:10.1001/archopht.121.8.1099 · Cited by 258 · cited 1×
“Therefore, it is reasonable to speculate that iron storage may contribute to AMD [83].”
BackgroundDo blue light filters confer protection against age-related macular degeneration?
MARGRAIN, T. (2004) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2004.05.001 · Cited by 257
Anderson, D. H., Ozaki, S., Nealon, M., Neitz, J., Mullins, R. F., Hageman, G. S., & Johnson, L. V. (2001) · American Journal of Ophthalmology · doi:10.1016/s0002-9394(00)00961-2 · Cited by 255 · cited 4×
“There is strong evidence that the rs1061170 CFH genetic variant tightly correlates to AMD [35,36] as it reduces the strength of the bond to heparan sulfate proteoglycans [58], causing lipoprotein deposition in Bruch’s membrane (BrM) and, consequently, drusen progression.”
BackgroundInfluentialHypoxia induces a novel signature of chromatin modifications and global repression of transcription
Johnson, A. B., Denko, N., & Barton, M. C. (2008) · Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis · doi:10.1016/j.mrfmmm.2008.01.001 · Cited by 250 · cited 1×
“AMD’s wet form [16], but oxidized cholesterol [17], inflammation, and modification of transcript events also seem to be related to angiogenetic events [18,19].”
BackgroundJakobsdottir, J., Gorin, M. B., Conley, Y. P., Ferrell, R. E., & Weeks, D. E. (2009) · PLoS Genetics · doi:10.1371/journal.pgen.1000337 · Cited by 245
Heier, J. S., Kherani, S., Desai, S., Dugel, P., Kaushal, S., Cheng, S. H., Delacono, C., Purvis, A., Richards, S., Le-Halpere, A., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)30979-0 · Cited by 229
The Membrane Attack Complex in Aging Human Choriocapillaris
Mullins, R. F., Schoo, D. P., Sohn, E. H., Flamme-Wiese, M. J., Workamelahu, G., Johnston, R. M., Wang, K., Tucker, B. A., & Stone, E. M. (2014) · The American Journal of Pathology · doi:10.1016/j.ajpath.2014.07.017 · Cited by 228
Toll-like Receptor 3 and Geographic Atrophy in Age-Related Macular Degeneration
Yang, Z., Stratton, C., Francis, P. J., Kleinman, M. E., Tan, P. L., Gibbs, D., Tong, Z., Chen, H., Constantine, R., Yang, X., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802437 · Cited by 222 · cited 11×
“A clinical trial (NCT04439708) is now ongoing to disclose biomarkers in the blood and aqueous humor in a population of AMD with occult CNV and analyse their relationship with the response to anti-VEGF treatment; another one (NCT05038371) aims to measure levels of connective tissue growth factor (CTGF) in the aqueous h…”
BackgroundInfluentialTIMP-3 in Bruch's membrane: changes during aging and in age-related macular degeneration.
Kamei, M., & Hollyfield, J. G. (1999) · PubMed · Cited by 206
The 2 and 4 Alleles of the Apolipoprotein Gene Are Associated with Age-Related Macular Degeneration
Baird, P. N. (2004) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.03-1121 · Cited by 201
Geerlings, M. J., de Jong, E. K., & den Hollander, A. I. (2017) · Molecular Immunology · doi:10.1016/j.molimm.2016.11.016 · Cited by 201
Recommendations for Genetic Testing of Inherited Eye Diseases
Stone, E. M., Aldave, A. J., Drack, A. V., MacCumber, M. W., Sheffield, V. C., Traboulsi, E., & Weleber, R. G. (2012) · Ophthalmology · doi:10.1016/j.ophtha.2012.05.047 · Cited by 195
Complement factor H in host defense and immune evasion
Parente, R., Clark, S. J., Inforzato, A., & Day, A. J. (2017) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-016-2418-4 · Cited by 193 · cited 1×
“There is strong evidence that the rs1061170 CFH genetic variant tightly correlates to AMD [35,36] as it reduces the strength of the bond to heparan sulfate proteoglycans [58], causing lipoprotein deposition in Bruch’s membrane (BrM) and, consequently, drusen progression.”
BackgroundSelf-citationA functional variant in the CFI gene confers a high risk of age-related macular degeneration
van de Ven, J. P. H., Nilsson, S. C., Tan, P. L., Buitendijk, G. H. S., Ristau, T., Mohlin, F. C., Nabuurs, S. B., Schoenmaker-Koller, F. E., Smailhodzic, D., Campochiaro, P. A., et al. (2013) · Nature Genetics · doi:10.1038/ng.2640 · Cited by 187 · cited 1×
“The rs2285714 carriers have been proven to be powerfully associated with AMD risk [44], and the mutation may serve as a biomarker [45], while rs10033900 may reduce the risk of AMD.”
BackgroundSepp, T., Khan, J. C., Thurlby, D. A., Shahid, H., Clayton, D. G., Moore, A. T., Bird, A. C., & Yates, J. R. W. (2006) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.05-1143 · Cited by 186
Lentiviral Vector Gene Transfer of Endostatin/Angiostatin for Macular Degeneration (GEM) Study
Campochiaro, P. A., Lauer, A. K., Sohn, E. H., Mir, T. A., Naylor, S., Anderton, M. C., Kelleher, M., Harrop, R., Ellis, S., & Mitrophanous, K. A. (2017) · Human Gene Therapy · doi:10.1089/hum.2016.117 · Cited by 186
Oxidative Stress Renders Retinal Pigment Epithelial Cells Susceptible to Complement-mediated Injury
Thurman, J. M., Renner, B., Kunchithapautham, K., Ferreira, V. P., Pangburn, M. K., Ablonczy, Z., Tomlinson, S., Holers, V. M., & Rohrer, B. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m808166200 · Cited by 185 · cited 1×
“Oxidative stress hinders RPE cells in controlling the activation of the complement system on their surface [12].”
BackgroundLing, S., Yang, S., Hu, X., Yin, D., Dai, Y., Qian, X., Wang, D., Pan, X., Hong, J., Sun, X., et al. (2021) · Nature Biomedical Engineering · doi:10.1038/s41551-020-00656-y · Cited by 179
CCL2 Regulates Angiogenesis via Activation of Ets-1 Transcription Factor
Stamatovic, S. M., Keep, R. F., Mostarica-Stojkovic, M., & Andjelkovic, A. V. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.177.4.2651 · Cited by 177 · cited 1×
“The chemokine receptors CX3CR1 and CCR-2 are displayed on macrophage surfaces after their activation and it has been suggested that they have a role in the angiogenic process for chemokine CCL2 through VEGF modulation [76].”
BackgroundFerreira, V. P., Herbert, A. P., Cortés, C., McKee, K. A., Blaum, B. S., Esswein, S. T., Uhrín, D., Barlow, P. N., Pangburn, M. K., & Kavanagh, D. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0804031 · Cited by 173 · cited 1×
“Furthermore, rare CFH mutations have been disclosed and they are presumed to create meaningful disease phenotype features and earlier onset disease [64]: rs121913059 [38] shows increased risk regardless of the common variants.”
BackgroundAge-related macular degeneration and the complement system
Khandhadia, S., Cipriani, V., Yates, J. R. W., & Lotery, A. J. (2012) · Immunobiology · doi:10.1016/j.imbio.2011.07.019 · Cited by 167
Hecker, L. A., Edwards, A. O., Ryu, E., Tosakulwong, N., Baratz, K. H., Brown, W. L., Issa, P. C., Scholl, H. P. N., Pollok‐Kopp, B., Schmid‐Kubista, K. E., et al. (2009) · Human Molecular Genetics · doi:10.1093/hmg/ddp472 · Cited by 164
The complotype: dictating risk for inflammation and infection
Harris, C. L., Heurich, M., Cordoba, S. R. D., & Morgan, B. P. (2012) · Trends in Immunology · doi:10.1016/j.it.2012.06.001 · Cited by 163 · cited 1×
“Several lines of evidence support the idea that the complotype ranks a person at a certain level on a range from low to high intrinsic predisposition to complement activation [80].”
BackgroundThe lipofuscin fluorophore A2E perturbs cholesterol metabolism in retinal pigment epithelial cells
Lakkaraju, A., Finnemann, S. C., & Rodriguez-Boulan, E. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0702504104 · Cited by 162 · cited 1×
“Through photooxidation and in the presence of a photosensitizer such as lipofuscin, cholesterol is converted into hydroperoxide intermediates that can further oxidize to 7kCh [22].”
BackgroundJoly, S., Francke, M., Ulbricht, E., Beck, S. C., Seeliger, M. W., Hirrlinger, P. G., Hirrlinger, J., Lang, K. S., Zinkernagel, M. S., Odermatt, B., et al. (2009) · American Journal Of Pathology · doi:10.2353/ajpath.2009.090023 · Cited by 161 · cited 1×
“Oxidative stress is a potential connection between the two systems, as lipid peroxidation products are capable of directly activating both M1 macrophages, whose recruitment is crucial to remove photoreceptor debris [10], and antigen-specific T cells [11].”
BackgroundRodríguez, I. R., & Larráyoz, I. M. (2010) · Journal of Lipid Research · doi:10.1194/jlr.r004820 · Cited by 149 · cited 1×
“The increased number of lipid-saturated dysfunctional macrophages, called foam cells, is an important factor of local inflammation and a key event in the development of atherosclerosis, whose process resembles what happens in the retina during AMD development [20].”
BackgroundKavanagh, D., Yu, Y., Schramm, E. C., Triebwasser, M. P., Wagner, E. K., Raychaudhuri, S., Daly, M. J., Atkinson, J. P., & Seddon, J. M. (2015) · Human Molecular Genetics · doi:10.1093/hmg/ddv091 · Cited by 147
Thakkinstian, A., McKay, G. J., McEvoy, M., Chakravarthy, U., Chakrabarti, S., Silvestri, G., Kaur, I., Li, X., & Attia, J. (2011) · American Journal of Epidemiology · doi:10.1093/aje/kwr025 · Cited by 143
Elevated membrane attack complex in human choroid with high risk complement factor H genotypes
Mullins, R. F., Dewald, A. D., Streb, L. M., Wang, K., Kuehn, M. H., & Stone, E. M. (2011) · Experimental Eye Research · doi:10.1016/j.exer.2011.06.015 · Cited by 135 · cited 2×
“Similar disputes were carried out for plasma levels of MAC components [7,116].”
BackgroundMethodRegulation of regulators: Role of the complement factor H-related proteins
Cserhalmi, M., Papp, A., Brandus, B., Uzonyi, B., & Józsi, M. (2019) · Seminars in Immunology · doi:10.1016/j.smim.2019.101341 · Cited by 131 · cited 1×
“According to multiple studies, the deletion in those sequences exercises a protective role on AMD [69].”
BackgroundOxidative stress promotes ocular neovascularization
Dong, A., Xie, B., Shen, J., Yoshida, T., Yokoi, K., Hackett, S. F., & Campochiaro, P. A. (2009) · Journal of Cellular Physiology · doi:10.1002/jcp.21698 · Cited by 129 · cited 1×
“AMD’s wet form [16], but oxidized cholesterol [17], inflammation, and modification of transcript events also seem to be related to angiogenetic events [18,19].”
BackgroundYu, Y., Reynolds, R. C., Fagerness, J. A., ROSNER, B. A., Daly, M. J., & Seddon, J. M. (2011) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.10-7070 · Cited by 128 · cited 2×
“rs1883025 is associated with decreased risk of AMD development [55,91] while rs2740488 is associated with increased risk [33].”
BackgroundKimura, K., Isashiki, Y., Sonoda, S., Kakiuchi, T., & Ohba, N. (2000) · American Journal of Ophthalmology · doi:10.1016/s0002-9394(00)00552-3 · Cited by 128 · cited 1×
“Studies have found a significant correlation between the MnSOD gene Ala-9Val, Ile58Thr polymorphism, and wet AMD [52].”
BackgroundIncreased postischemic brain injury in mice deficient in uracil-DNA glycosylase
Endres, M., Biniszkiewicz, D., Sobol, R. W., Harms, C., Ahmadi, M., Lipski, A., Katchanov, J., Mergenthaler, P., Dirnagl, U., Wilson, S. H., et al. (2004) · Journal of Clinical Investigation · doi:10.1172/jci200420926 · Cited by 128
Marmorstein, L. Y., McLaughlin, P. J., Peachey, N. S., Sasaki, T., & Marmorstein, A. D. (2007) · Human Molecular Genetics · doi:10.1093/hmg/ddm199 · Cited by 127 · cited 1×
“Even if it is not an intrinsic component of drusen, it may lead to their deposition and the ensuing macular injury [98].”
BackgroundGrishanin, R., Vuillemenot, B., Sharma, P., Keravala, A., Greengard, J., Gelfman, C., Blumenkrantz, M., Lawrence, M., Hu, W., Kiss, S., et al. (2019) · Molecular Therapy · doi:10.1016/j.ymthe.2018.11.003 · Cited by 127
Review of gene therapies for age-related macular degeneration
Khanani, A. M., Thomas, M. J., Aziz, A. A., Weng, C. Y., Danzig, C. J., Yiu, G., Kiss, S., Waheed, N. K., & Kaiser, P. K. (2022) · Eye · doi:10.1038/s41433-021-01842-1 · Cited by 119
Gorin, M. B. (2012) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2012.04.004 · Cited by 113
The eye as a complement dysregulation hotspot
Clark, S. J., & Bishop, P. N. (2017) · Seminars in Immunopathology · doi:10.1007/s00281-017-0649-6 · Cited by 113
Chong, E. W.-T., Kreis, A. J., Wong, T. Y., Simpson, J. A., & Guymer, R. H. (2008) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2007.12.005 · Cited by 112 · cited 1×
“Additionally, other minor factors such as alcohol consumption [27], light exposure [28], and high blood pressure [29] have been associated with AMD.”
BackgroundParekh, N., Voland, R. P., Moeller, S. M., Blodi, B. A., Ritenbaugh, C., Chappell, R. J., Wallace, R. B., & Mares, J. A. (2009) · Archives of Ophthalmology · doi:10.1001/archophthalmol.2009.130 · Cited by 111 · cited 1×
“The AREDS research group found that the integration of high-dose antioxidants and zinc reduced the progression to late AMD, suggesting that dietary elements can contribute to the risk of AMD [26].”
Increased postischemic brain injury in mice deficient in uracil-DNA glycosylase
Endres, M., Biniszkiewicz, D., Sobol, R. W., et al. (2004) · Journal of Clinical Investigation · doi:10.1172/jci20926 · Cited by 111 · cited 1×
“In order to preserve DNA integrity, mechanisms for the DNA reparation are needed [92].”
BackgroundMoreira, E. F., Larráyoz, I. M., Lee, J. W., & Rodríguez, I. R. (2009) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.08-2373 · Cited by 108 · cited 1×
“AMD’s wet form [16], but oxidized cholesterol [17], inflammation, and modification of transcript events also seem to be related to angiogenetic events [18,19].”
BackgroundThe challenges and promise of complement therapeutics for ocular diseases
Park, D. H., Connor, K. M., & Lambris, J. D. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01007 · Cited by 108 · cited 1×
“There is strong evidence that the rs1061170 CFH genetic variant tightly correlates to AMD [35,36] as it reduces the strength of the bond to heparan sulfate proteoglycans [58], causing lipoprotein deposition in Bruch’s membrane (BrM) and, consequently, drusen progression.”
BackgroundMo, F. M., Proia, A. D., Johnson, W. H., Cyr, D., & Lashkari, K. (2010) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.09-3910 · Cited by 105
An Eye on Age-Related Macular Degeneration: The Role of MicroRNAs in Disease Pathology
Berber, P., Graßmann, F., Kiel, C., & Weber, B. H. F. (2016) · Molecular Diagnosis & Therapy · doi:10.1007/s40291-016-0234-z · Cited by 105 · cited 1×
“miRNA can interfere with gene expression: many studies have suggested that dysregulated miRNAs may be involved in AMD pathology [32].”
BackgroundKumar‐Singh, R. (2019) · Experimental Eye Research · doi:10.1016/j.exer.2019.05.006 · Cited by 101 · cited 1×
“Sub-lytic MAC induces damage at the chorioretinal interface [7], elevating inflammatory mediators and molecules of tissue remodelling, increasing expression of adhesion molecules, activating inflammasome, and altering the balance between vascular endothelial growth factor (VEGF) and anti-angiogenic molecules [8,9].”
BackgroundCipriani, V., Lorés-Motta, L., He, F., Fathalla, D., Tilakaratna, V., McHarg, S., Bayatti, N., Acar, İ. E., Hoyng, C. B., Fauser, S., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-14499-3 · Cited by 101 · cited 1×
“Altered FHR circulating levels have been reported in late AMD and to be associated with different genetic determinants [70].”
BackgroundFritsche, L. G., Fleckenstein, M., Fiebig, B. S., Schmitz-Valckenberg, S., Bindewald-Wittich, A., Keilhauer, C. N., Renner, A. B., Mackensen, F., Mößner, A., Pauleikhoff, D., et al. (2012) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.11-8785 · Cited by 99
Complement Factor D in Age-Related Macular Degeneration
Stanton, C. M., Yates, J. R. W., den Hollander, A. I., Seddon, J. M., Swaroop, A., Stambolian, D., Fauser, S., Hoyng, C., Yu, Y., Atsuhiro, K., et al. (2011) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.11-7933 · Cited by 99
Developments in anti-complement therapy; from disease to clinical trial
Harris, C. L., Pouw, R. B., Kavanagh, D., Sun, R., & Ricklin, D. (2018) · Molecular Immunology · doi:10.1016/j.molimm.2018.06.008 · Cited by 99
Prediction of Age-related Macular Degeneration in the General Population
Buitendijk, G. H. S., Rochtchina, E., Myers, C., van Duijn, C. M., Lee, K. E., Klein, B. E. K., Meuer, S. M., de Jong, P. T. V. M., Holliday, E. G., Tan, A. G., et al. (2013) · Ophthalmology · doi:10.1016/j.ophtha.2013.07.053 · Cited by 94
Yu, T., Liao, J., Zhang, Y., Zhou, J., Zhang, H., & Mao, M. (2010) · PubMed Central · Cited by 91
Integrating Metabolomics, Genomics, and Disease Pathways in Age-Related Macular Degeneration
Acar, İ. E., Lorés‐Motta, L., Colijn, J. M., Meester‐Smoor, M. A., Verzijden, T., Cougnard‐Grégoire, A., Ajana, S., Merle, B. M. J., de Breuk, A., Heesterbeek, T. J., et al. (2020) · Ophthalmology · doi:10.1016/j.ophtha.2020.06.020 · Cited by 91
Complement inhibition as a therapeutic strategy in retinal disorders
Kassa, E., Ciulla, T. A., Hussain, R. M., & Dugel, P. U. (2019) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2019.1575358 · Cited by 89
Abedi, F., Wickremasinghe, S., Richardson, A. J., Islam, A. F. M., Guymer, R. H., & Baird, P. N. (2013) · Ophthalmology · doi:10.1016/j.ophtha.2013.01.014 · Cited by 82
Lueck, K., Wasmuth, S., Williams, J., Hughes, T. R., Morgan, B. P., Lommatzsch, A., Greenwood, J., Moss, S. E., & Pauleikhoff, D. (2011) · Eye · doi:10.1038/eye.2011.109 · Cited by 80 · cited 1×
“Sub-lytic MAC induces damage at the chorioretinal interface [7], elevating inflammatory mediators and molecules of tissue remodelling, increasing expression of adhesion molecules, activating inflammasome, and altering the balance between vascular endothelial growth factor (VEGF) and anti-angiogenic molecules [8,9].”
BackgroundComplement Factor H Variant Increases the Risk of Age-Related Macular Degeneration
Eagle, R. C. (2006) · Yearbook of Ophthalmology · doi:10.1016/s0084-392x(08)70396-4 · Cited by 80
Towards the application of precision medicine in Age-Related Macular Degeneration
Cascella, R., Strafella, C., Caputo, V., Errichiello, V., Zampatti, S., Milano, F., Potenza, S., Mauriello, S., Novelli, G., Ricci, F., et al. (2018) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2017.11.004 · Cited by 76
Cruz‐Guilloty, F., Saeed, A. M., Duffort, S., Cano, M., Ebrahimi, K. B., Ballmick, A., Tan, Y., Wang, H., Laird, J. M., Salomon, R. G., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0088201 · Cited by 75 · cited 1×
“Oxidative stress is a potential connection between the two systems, as lipid peroxidation products are capable of directly activating both M1 macrophages, whose recruitment is crucial to remove photoreceptor debris [10], and antigen-specific T cells [11].”
BackgroundAge-related macular degeneration: a perspective on genetic studies
Patel, N., Adewoyin, T., & Chong, V. N. (2007) · Eye · doi:10.1038/sj.eye.6702844 · Cited by 71 · cited 1×
“This condition mainly affects central vision; therefore, it is the major cause of visual acuity (VA)-lowering and blindness in the over-60-years-old population [2].”
BackgroundMori, K., Gehlbach, P. L., Kabasawa, S., Kawasaki, I., Oosaki, M., Iizuka, H., Katayama, S., Awata, T., & Yoneya, S. (2007) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.07-0426 · Cited by 70
Genetic Determinants of Age-Related Macular Degeneration in Diverse Populations From the PAGE Study
Restrepo, N. A., Spencer, K. L., Goodloe, R., Garrett, T. A., HEISS, G. M., kova, P. B., Jorgensen, N. W., Jensen, R. A., Matise, T. C., Hindorff, L. A., et al. (2014) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.14-14246 · Cited by 70 · cited 1×
“Even though the true contribution of aberrant lipid regulation needs to be fully understood, the literature reports its involvement in AMD pathobiology, especially that of the high-density lipoprotein (HDL) cholesterol [84].”
BackgroundDevelopment of a Genotype Assay for Age-Related Macular Degeneration
de Breuk, A., Acar, İ. E., Kersten, E., Schijvenaars, M. M. V. A. P., Colijn, J. M., Haer‐Wigman, L., Bakker, B., de Jong, S., Meester‐Smoor, M. A., Verzijden, T., et al. (2020) · Ophthalmology · doi:10.1016/j.ophtha.2020.07.037 · Cited by 70
Rare Genetic Variants Associated With Development of Age-Related Macular Degeneration
Saksens, N. T. M., Geerlings, M. J., Bakker, B., Schick, T., Daha, M. R., Fauser, S., Boon, C. J. F., de Jong, E. K., Hoyng, C. B., & den Hollander, A. I. (2016) · JAMA Ophthalmology · doi:10.1001/jamaophthalmol.2015.5592 · Cited by 69
Mechanism of Inflammation in Age-Related Macular Degeneration: An Up-to-Date on Genetic Landmarks
Parmeggiani, F., Sorrentino, F. S., Romano, M. R., Costagliola, C., Semeraro, F., Incorvaia, C., D’Angelo, S., Perri, P., Nadai, K. D., Roversi, E. B., et al. (2013) · Mediators of Inflammation · doi:10.1155/2013/435607 · Cited by 67 · cited 1×
“Furthermore, two main mechanisms of oxidation of cholesterol have been described in the retina: the Fenton reaction and photooxidation [21].”
BackgroundSelf-citationLorés‐Motta, L., van Beek, A. E., Willems, E., Zandstra, J., van Mierlo, G. J., Einhaus, A., Mary, J.-L., Stucki, C., Bakker, B., Hoyng, C. B., et al. (2021) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2021.06.002 · Cited by 67 · cited 1×
“The role of CFHR is still largely to be investigated but they are assumed to take part in complement regulation by competing with FH [68].”
BackgroundLong-Term Blood Pressure and Age-Related Macular Degeneration: The ALIENOR Study
Cougnard‐Grégoire, A., Delyfer, M., Korobelnik, J., Rougier, M., Malet, F., Goff, M. L., Dartigues, J., Colin, J., Barberger‐Gateau, P., & Delcourt, C. (2013) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.12-10192 · Cited by 66 · cited 1×
“Additionally, other minor factors such as alcohol consumption [27], light exposure [28], and high blood pressure [29] have been associated with AMD.”
BackgroundMorohoshi, K., Patel, N., Ohbayashi, M., Chong, V. N., Grossniklaus, H. E., Bird, A. C., & Ono, S. J. (2011) · Experimental and Molecular Pathology · doi:10.1016/j.yexmp.2011.09.017 · Cited by 65
Thakkinstian, A., McEvoy, M., Chakravarthy, U., Chakrabarti, S., McKay, G. J., Ryu, E., Silvestri, G., Kaur, I., Francis, P. J., Iwata, T., et al. (2012) · American Journal of Epidemiology · doi:10.1093/aje/kws031 · Cited by 65 · cited 1×
“CFB rs641153 and rs415667 polymorphisms are associated with a protective effect for AMD and the presence of the C2 rs9332739 and rs547154 variants has been shown to reduce the progression to advanced AMD [41,42].”
BackgroundDevelopment of an inducible anti-VEGF rAAV gene therapy strategy for the treatment of wet AMD
Reid, C. A., Nettesheim, E. R., Connor, T. B., & Lipinski, D. M. (2018) · Scientific Reports · doi:10.1038/s41598-018-29726-7 · Cited by 65
Gene therapy for age-related macular degeneration
Moore, N. A., Bracha, P., Hussain, R. M., Morral, N., & Ciulla, T. A. (2017) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2017.1356817 · Cited by 63
Bivariate Analysis of Age-Related Macular Degeneration Progression Using Genetic Risk Scores
Ding, Y., Liu, Y., Yan, Q., Fritsche, L. G., Cook, R. J., Clemons, T. E., Ratnapriya, R., Klein, M. L., Abecasis, G. R., Swaroop, A., et al. (2017) · Genetics · doi:10.1534/genetics.116.196998 · Cited by 60
Wagner, E. K., Raychaudhuri, S., Villalonga, M. B., Java, A., Triebwasser, M. P., Daly, M. J., Atkinson, J. P., & Seddon, J. M. (2016) · Scientific Reports · doi:10.1038/srep31531 · Cited by 59
Wickremasinghe, S. S., Xie, J., Lim, J., Chauhan, D. S., Robman, L., Richardson, A. J., Hageman, G., Baird, P. N., & Guymer, R. (2011) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.10-6550 · Cited by 58
Genetic markers and biomarkers for age-related macular degeneration
Ross, R. J., Verma, V. K., Rosenberg, K. I., Chan, C., & Tuo, J. (2007) · Expert Review of Ophthalmology · doi:10.1586/17469899.2.3.443 · Cited by 58
Paun, C. C., Ersoy, L., Schick, T., Groenewoud, J. M. M., Lechanteur, Y. T. E., Fauser, S., Hoyng, C. B., de Jong, E. K., & den Hollander, A. I. (2015) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.15-17035 · Cited by 57
Silva, A. S., Teixeira, A., Bavia, L., Lin, F. L. H., Velletri, R., Belfort, R., & Isaac, L. (2012) · PubMed Central · Cited by 56
Steinle, N. C., Pearce, I., Monés, J., Metlapally, R., Saroj, N., Hamdani, M., Ribeiro, R., Rosenfeld, P. J., & Lad, E. M. (2021) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2021.02.031 · Cited by 55
Seddon, J. M., & ROSNER, B. A. (2018) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2018.10.022 · Cited by 54
Ferrara, D., & Seddon, J. M. (2015) · JAMA Ophthalmology · doi:10.1001/jamaophthalmol.2015.0814 · Cited by 52
Sharma, N. K., Gupta, A., Prabhakar, S. K., Singh, R., Sharma, S., Chen, W., & Anand, A. (2013) · PLoS ONE · doi:10.1371/journal.pone.0070193 · Cited by 52 · cited 1×
“[63] reported significantly lower serum CFH levels in the AMD Y402H variant of CFH compared to controls, showing its potential role as a biomarker for the disease.”
BackgroundOxidative stress‐induced angiogenesis is mediated by miR‐205‐5p
Oltra, M. R., Vidal‐Gil, L., Maisto, R., Sancho-Pellúz, J., & Barcia, J. M. (2019) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.14822 · Cited by 51 · cited 1×
“AMD’s wet form [16], but oxidized cholesterol [17], inflammation, and modification of transcript events also seem to be related to angiogenetic events [18,19].”
BackgroundHalawa, O. A., Lin, J. B., Miller, J. W., & Vavvas, D. G. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10122580 · Cited by 48
Hong, N., Shen, Y., Yu, C., Wang, S., & Tong, J. (2016) · Acta Ophthalmologica · doi:10.1111/aos.13049 · Cited by 47
Chen, W., Xu, W., Tao, Q., Liu, J., Li, X., Gan, X., Hu, H., & Lu, Y. (2008) · Experimental Eye Research · doi:10.1016/j.exer.2008.10.017 · Cited by 46 · cited 1×
“Other reports identified the regulatory region HTRA1 rs11200638 [50,51].”
BackgroundTsai, D., Charng, M., Lee, F.-L., Hsu, W., & Chen, S. (2006) · Ophthalmologica · doi:10.1159/000093079 · Cited by 45
The Aging Stress Response and Its Implication for AMD Pathogenesis
Blasiak, J., Pawlowska, E., Sobczuk, A., Szczepanska, J., & Kaarniranta, K. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21228840 · Cited by 44 · cited 1×
“Other environmental elements may strengthen such changes [24].”
BackgroundCurrent phase 1/2 research for neovascular age-related macular degeneration
Pecen, P. E., & Kaiser, P. K. (2015) · Current Opinion in Ophthalmology · doi:10.1097/icu.0000000000000147 · Cited by 43
PHARMACOGENOMICS OF RESPONSE TO ANTI-VEGF THERAPY IN EXUDATIVE AGE-RELATED MACULAR DEGENERATION
Dedania, V. S., Grob, S., Zhang, K., & Bakri, S. J. (2015) · Retina · doi:10.1097/iae.0000000000000466 · Cited by 42
Mullins, R. F., McGwin, G., Searcey, K., Clark, M. E., Kennedy, E. L., Curcio, C. A., Stone, E. M., & Owsley, C. J. (2018) · Ophthalmology · doi:10.1016/j.ophtha.2018.10.037 · Cited by 42 · cited 1×
“The rs10490924/A69S polymorphism, which surrounds two genes, ARMS2 and HTRA1, has been reproducibly observed as a strong genetic risk factor for AMD [46,47].”
BackgroundFauser, S., & Lambrou, G. N. (2014) · Survey of Ophthalmology · doi:10.1016/j.survophthal.2014.11.002 · Cited by 41
Zhao, L., Grob, S., Avery, R. L., KIMURA, A. E., Pieramici, D. J., Lee, J., Rabena, M., Ortiz, S. O., Quach, J., Cao, G., et al. (2013) · Current Molecular Medicine · doi:10.2174/15665240113139990048 · Cited by 39 · cited 1×
“Various SNPs, particularly rs943080, affect VEGF and VEGFR-2 levels, collaborating with the pathogenesis of neovascularization and impacting on the response to anti-VEGF treatment [56,57]”
BackgroundCorrection: Systemic Complement Activation in Age-Related Macular Degeneration
Scholl, H. P. N., Charbel Issa, P., Walier, M., Janzer, S., Pollok-Kopp, B., Börncke, F., Fritsche, L. G., Chong, N. V., Fimmers, R., Wienker, T., et al. (2008) · PLoS ONE · doi:10.1371/annotation/32b9bc31-ed6d-4d31-9ce0-480407017bad · Cited by 39
Polymorphisms of the DNA Repair Genes XPD and XRCC1 and the Risk of Age-Related Macular Degeneration
Görgün, E., Güven, M., Ünal, M., Batar, B., Güven, G. S., Yenerel, N. M., Tatlıpınar, S., Seven, M., & Yüksel, A. (2010) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.09-4842 · Cited by 38 · cited 1×
“Therefore, genetic variants of XPD could affect the efficiency of NER, cause DNA alteration, and contribute to the development of AMD [93].”
BackgroundPaun, C. C., Lechanteur, Y. T. E., Groenewoud, J. M. M., Altay, L., Schick, T., Daha, M. R., Fauser, S., Hoyng, C. B., den Hollander, A. I., & de Jong, E. K. (2016) · Scientific Reports · doi:10.1038/srep26568 · Cited by 38 · cited 1×
“These observations find practical relevance in the light of the new complement-modulating therapies that are now in the process of being developed: patients with a higher tendency for complement activation are more likely to take advantage of such therapeutic options [81].”
BackgroundEpigenetics in Age-related Macular Degeneration (AMD)
Desmettre, T. J. (2018) · Journal Français d Ophtalmologie · doi:10.1016/j.jfo.2018.09.001 · Cited by 38 · cited 7×
“The elevated metabolism of the retina exposes the tissue to an important load of oxidative stress [31], which is a mechanism of cellular damage determined by the loss of equilibrium between ROS creation and elimination.”
BackgroundInfluentialNagineni, C. N., Kommineni, V. K., Ganjbaksh, N., Nagineni, K. K., Hooks, J. J., & Detrick, B. (2015) · Aging and Disease · doi:10.14336/ad.2015.0323 · Cited by 37 · cited 1×
“Many studies agree on the relationship in AMD between the inflammatory system, chemokines, and their corresponding ligands [75].”
BackgroundDark Matters in AMD Genetics: Epigenetics and Stochasticity
Hjelmeland, L. M. (2011) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.10-6765 · Cited by 35 · cited 12×
“Since then, subsequent GWASs for variants of candidate genes of the complement cascade, oxidative stress, lipid metabolism, DNA damage repairing, and neo-angiogenesis have been associated with AMD.”
BackgroundInfluentialSynowiec, E., Szaflik, J., Chmielewska, M., Woźniak, K., Skłodowska, A., Waszczyk, M., Dorecka, M., Błasiak, J., & Szaflik, J. P. (2011) · Molecular Biology Reports · doi:10.1007/s11033-011-0955-3 · Cited by 33 · cited 1×
“HMOX1 polymorphism rs2071747 was found to be associated with AMD evolution to the wet form, and HMOX2 polymorphism rs2270363 was associated with dry AMD [54].”
BackgroundRen, X., Li, J., Xu, X., Wang, C., & Cheng, Y. (2016) · Experimental Eye Research · doi:10.1016/j.exer.2016.02.004 · Cited by 32
DNA Damage/Repair and Polymorphism of the hOGG1 Gene in Lymphocytes of AMD Patients
Woźniak, K., Szaflik, J. P., Zaraś, M., Skłodowska, A., Janik-Papis, K., Popławski, T., Błasiak, J., & Szaflik, J. (2009) · BioMed Research International · doi:10.1155/2009/827562 · Cited by 30 · cited 1×
“The role of DNA repair in cell response to oxidative stress gives reason for the potential association between polymorphisms of DNA repair genes and risk of developing AMD [14,15].”
BackgroundLu, F., Liu, S., Hao, Q.-Y., Liu, L., Zhang, J., Chen, X., Wang, H., & Huang, P. (2018) · Genetic Testing and Molecular Biomarkers · doi:10.1089/gtmb.2018.0110 · Cited by 30 · cited 1×
“The products of the photo-oxidation of RPE lipofuscin trigger the complement system, contributing to chronic inflammation over time [23].”
BackgroundWarwick, A., Gibson, J., Sood, R. K., & Lotery, A. J. (2015) · Eye · doi:10.1038/eye.2015.204 · Cited by 29
Genetic Variability in DNA Repair Proteins in Age-Related Macular Degeneration
Błasiak, J., Synowiec, E., Salminen, A., & Kaarniranta, K. (2012) · International Journal of Molecular Sciences · doi:10.3390/ijms131013378 · Cited by 29 · cited 2×
“Overall, further investigations are needed to identify genetic variants of proteins responsible for recognition and removal of oxidative DNA damage [14].”
BackgroundDuvvari, M. R., Saksens, N. T. M., van de Ven, J. P. H., de Jong‐Hesse, Y., Schick, T., Nillesen, W. M., Fauser, S., Hoefsloot, L. H., Hoyng, C. B., de Jong, E. K., et al. (2015) · Europe PMC (PubMed Central) · Cited by 28
Jones, R., Ridley, C. E., Jowitt, T. A., Wang, M.-C., Howard, M., Bobola, N., Wang, T., Bishop, P. N., Kielty, C. M., Baldock, C., et al. (2010) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.09-4620 · Cited by 28 · cited 3×
“Mutations in FBLN5 have been correlated to cuticular drusen [109,110].”
BackgroundInfluentialKowalski, M., Bielecka-Kowalska, A., Oszajca, K., Eusebio, M.-O., Jaworski, P., Bartkowiak, J., & Szemraj, J. (2010) · PubMed · Cited by 26
Risk Stratification and Clinical Utility of Polygenic Risk Scores in Ophthalmology
Qassim, A., Souzeau, E., Hollitt, G. L., Hassall, M., Siggs, O. M., & Craig, J. E. (2021) · Translational Vision Science & Technology · doi:10.1167/tvst.10.6.14 · Cited by 26
Raimondi, R., Zollet, P., Rosa, F. P. D., Tsoutsanis, P., Stravalaci, M., Paulis, M., Inforzato, A., & Romano, M. R. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23020682 · Cited by 26
Self-citationThe Reduction of Serum Soluble Flt-1 in Patients With Neovascular Age-Related Macular Degeneration
Uehara, H., Mamalis, C., McFadden, M., Taggart, M. G., Stagg, B. C., Passi, S. F., Earle, P., Chakravarthy, U., Hogg, R. E., & Ambati, B. K. (2014) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2014.09.036 · Cited by 25
Development of IONIS-FB-LRx to Treat Geographic Atrophy Associated with AMD
Jaffe, G. J., Sahni, J., Fauser, S., Geary, R. S., Schneider, E., & McCaleb, M. L. (2020) · Investigative Ophthalmology & Visual Science · Cited by 25
Predictive Biomarkers of Age-Related Macular Degeneration Response to Anti-VEGF Treatment
Oca, A. I., Pérez-Sala, Á., Pariente, A., Ochoa, R., Velilla, S., Peláez, R., & Larráyoz, I. M. (2021) · Journal of Personalized Medicine · doi:10.3390/jpm11121329 · Cited by 25
Stravalaci, M., Ferrara, M., Pathak, V., Davi, F., Bottazzi, B., Mantovani, A., Medina, R. J., Romano, M. R., & Inforzato, A. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.811344 · Cited by 25
Self-citationKersten, E., Geerlings, M. J., den Hollander, A. I., de Jong, E. K., Fauser, S., Pető, T., & Hoyng, C. B. (2017) · JAMA Ophthalmology · doi:10.1001/jamaophthalmol.2017.3195 · Cited by 24
Highly Penetrant Alleles in Age-Related Macular Degeneration
den Hollander, A. I., & de Jong, E. K. (2014) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a017202 · Cited by 23 · cited 1×
“Although the mechanism of its functional influence on the terminal part of the complement cascade has yet to be established [73], this is the first link between a component of the MAC and the development of AMD.”
BackgroundMullins, R. F., Warwick, A., Sohn, E. H., & Lotery, A. J. (2017) · Human Molecular Genetics · doi:10.1093/hmg/ddx181 · Cited by 22
ABCA1 rs1883025 polymorphism and risk of age-related macular degeneration
Wang, Y., Wang, M., Han, Y., Zhang, R., & Ma, L. (2015) · Graefe s Archive for Clinical and Experimental Ophthalmology · doi:10.1007/s00417-015-3211-z · Cited by 21
Choroidal Neovascular Membranes Express Toll-Like Receptor 3
Maloney, S., Antecka, E., Orellana, M. E., Fernandes, B. F., Odashiro, A. N., Eghtedari, M., & Burnier, M. N. (2010) · Ophthalmic Research · doi:10.1159/000313989 · Cited by 20
Complement Factor B Polymorphism and the Phenotype of Early Age-related Macular Degeneration
Mantel, I., Ambresin, A., Moetteli, L., Droz, I., Roduit, R., Munier, F. L., & Schorderet, D. F. (2013) · Ophthalmic Genetics · doi:10.3109/13816810.2013.766217 · Cited by 20 · cited 1×
“Subsequentially, variation in R32Q polymorphism has been reconducted with a clinical type of AMD dominated by small drusen and it seems to prevent the evolution to large drusen [72].”
BackgroundYu, Q., Yao, Y., Zhu, J., Xin, B., Xie, T., Sun, C., & Cao, J. (2015) · Gene · doi:10.1016/j.gene.2015.02.039 · Cited by 18 · cited 1×
“Additionally, 71 rare missense variants were individuated, some of which were strongly associated with AMD [43,71].”
BackgroundJoachim, N., Kifley, A., Colijn, J. M., Lee, K. E., Buitendijk, G. H. S., Klein, R., Myers, C. E., Meuer, S. M., Tan, A. G., Flood, V. M., et al. (2017) · Ophthalmology Retina · doi:10.1016/j.oret.2017.10.019 · Cited by 18
de Breuk, A., Heesterbeek, T. J., Bakker, B., Verzijden, T., Lechanteur, Y. T. E., Klaver, C. C. W., den Hollander, A. I., & Hoyng, C. B. (2021) · JAMA Ophthalmology · doi:10.1001/jamaophthalmol.2021.4102 · Cited by 18 · cited 1×
“Furthermore, rare CFH mutations have been disclosed and they are presumed to create meaningful disease phenotype features and earlier onset disease [64]: rs121913059 [38] shows increased risk regardless of the common variants.”
BackgroundBalikova, I., Postelmans, L. D., Pasteels, B., Coquelet, P., Catherine, J., Efendic, A., Hosoda, Y., Miyake, M., Yamashiro, K., ANGEL study group members, et al. (2019) · BMJ Open Ophthalmology · doi:10.1136/bmjophth-2019-000273 · Cited by 17
Stravalaci, M., Davi, F., Parente, R., Gobbi, M., Bottazzi, B., Mantovani, A., Day, A. J., Clark, S. J., Romano, M. R., & Inforzato, A. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.591908 · Cited by 17
Self-citationKozhevnikova, O. S., Фурсова, А. Ж., Derbeneva, A. S., Nikulich, I. F., Сергеевич, Т. М., Devyatkin, V. A., Rumyantseva, Y. V., Telegina, D. V., & Kolosova, N. G. (2022) · Biomedicines · doi:10.3390/biomedicines10071658 · Cited by 17
Wang, Q., Zhao, H., & Li, L. (2016) · International Journal of Ophthalmology · doi:10.18240/ijo.2016.02.23 · Cited by 16 · cited 1×
“The rs2285714 carriers have been proven to be powerfully associated with AMD risk [44], and the mutation may serve as a biomarker [45], while rs10033900 may reduce the risk of AMD.”
BackgroundBiggs, R. M., Makou, E., Lauder, S., Herbert, A. P., Barlow, P. N., & Katti, S. K. (2022) · Current Eye Research · doi:10.1080/02713683.2022.2053725 · Cited by 16
Variations in TIMP3 are associated with age-related macular degeneration
Kaur, I., Rathi, S., & Chakrabarti, S. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1007476107 · Cited by 15 · cited 1×
“Overall, TIMP-3 is known to inhibit CNV, but its upregulated levels are also associated with macular thickening and ensuing RPE atrophy [96].”
BackgroundWang, X., Zhang, Y., & Zhang, M.-N. (2013) · International Journal of Ophthalmology · doi:10.3980/j.issn.2222-3959.2013.06.21 · Cited by 15 · cited 1×
“CFB rs641153 and rs415667 polymorphisms are associated with a protective effect for AMD and the presence of the C2 rs9332739 and rs547154 variants has been shown to reduce the progression to advanced AMD [41,42].”
BackgroundZhang, J., Liu, Z., Hu, S., & Qi, J. (2021) · Ophthalmic Research · doi:10.1159/000508738 · Cited by 15 · cited 2×
“ARMS2 A69S is a prognostic factor for an anti-VEGF response in wet AMD in the East Asian population, but not in the Caucasian or Middle Eastern group [48].”
BackgroundBakbak, B., Öztürk, B., Zamanı, A. G., Gönül, Ş., İyit, N., Gedik, Ş., & Yıldırım, M. S. (2015) · Current Eye Research · doi:10.3109/02713683.2015.1067325 · Cited by 13 · cited 1×
“[88] reported that mutated Apo ε4 shows consistently better VA after treatment with ranibizumab in exudative AMD.”
BackgroundRisk Factors for Age-Related Maculopathy: The Visual Impairment Project
McCarty, C. A. (2001) · Archives of Ophthalmology · doi:10.1001/archopht.119.10.1455 · Cited by 12 · cited 1×
“Long-time smokers have a significantly higher probability of developing disease than non-smokers of the same age [25].”
BackgroundComplement family member CFI polymorphisms and AMD susceptibility from a comprehensive analysis
Yu, Q., Zhu, J., Yao, Y., & Sun, C. (2020) · Bioscience Reports · doi:10.1042/bsr20200406 · Cited by 11 · cited 1×
“The CFI gene produces a serine proteinase that is crucial to the complement control [74].”
BackgroundWang, X., Geng, P., Zhang, Y., & Zhang, M.-N. (2014) · Gene · doi:10.1016/j.gene.2014.01.032 · Cited by 7
Arslan, J., & Baird, P. N. (2018) · Pharmacogenomics · doi:10.2217/pgs-2017-0183 · Cited by 7
HTRA1 rs11200638 variant and AMD risk from a comprehensive analysis about 15,316 subjects
Liu, Y., Jin, H., Wei, D., & Li, W. (2020) · BMC Medical Genetics · doi:10.1186/s12881-020-01047-5 · Cited by 7 · cited 1×
“polymorphism influences the anti-VEGF response in late-stage AMD, notably in the East Asian population [48], suggesting that the latter mutation may serve as a prognostic factor for the anti-VEGF response, especially in A-allele carriers or the AA genotype, whose detection may be an indication for early intervention […”
BackgroundDong, Y. N., Li, Z.-D., Fang, X., Shi, X., Chen, S., & Tang, X. (2015) · International Journal of Ophthalmology · doi:10.3980/j.issn.2222-3959.2015.02.31 · Cited by 6 · cited 1×
“It is found in the neural retina, RPE, and choroidal tissue and it was seen to play a predisposing role to AMD in Caucasians [77].”
BackgroundClinically detectable drusen domains in fibulin-5-associated age-related macular degeneration (AMD)
Küçükevcilioğlu, M., Patel, C. B., Stone, E. M., & Russell, S. R. (2015) · International Ophthalmology · doi:10.1007/s10792-015-0164-5 · Cited by 6
Yan, X., Zefeng, K., Li, L., & Ruijuan, G. (2021) · PLoS ONE · doi:10.1371/journal.pone.0251931 · Cited by 6 · cited 1×
“Some polymorphisms are thought to be associated with AMD [94].”
BackgroundWang, J., Wang, Y., Yu, D., Liu, Q., Lin, S., Tian, R., Li, J., & Luo, Y. (2021) · Ophthalmic Research · doi:10.1159/000515053 · Cited by 2
Revisiting the Question of Genetic Testing for Persons with Age-Related Macular Degeneration
Chew, E. Y. (2021) · Ophthalmology · doi:10.1016/j.ophtha.2021.07.002 · Cited by 2
Research works printed but not linked: 1
- Busbee, 2021, Phase 1 Study of Intravitreal Gene Therapy with ADVM-022 for neovascular AMD (OPTIC Trial), Investig. Ophthalmol. Vis. Sci., 62, 352
Cited by
Hernández, M. E. O., Luján, L. M. L., Burboa‐Zazueta, M. G., Castillo-Castro, T. D., Vega, E. D. L. R., Galvez-Ruiz, J. C., López, S. T., López‐Torres, M. A., & Assanga, S. B. I. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26083463 · Cited by 76
“Additionally, mutations in the CFH gene are known to elevate the risk of developing AMD [12,13].”
Different Therapeutic Approaches for Dry and Wet AMD
Marchesi, N., Capierri, M., Pascale, A., & Barbieri, A. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms252313053 · Cited by 71
“For this reason, variations in ARMS2/HTRA1 may lead, with a higher likelihood, to the development of wet AMD [32].”
Genetic Insights into Age-Related Macular Degeneration
Bhumika, Bora, N. S., & Bora, P. S. (2024) · Biomedicines · doi:10.3390/biomedicines12071479 · Cited by 35
Mimura, T., & Noma, H. (2025) · Antioxidants · doi:10.3390/antiox14101251 · Cited by 32
The impact of NF-κB on inflammatory and angiogenic processes in age-related macular degeneration
Almalki, W. H., & Almujri, S. S. (2024) · Experimental Eye Research · doi:10.1016/j.exer.2024.110111 · Cited by 22
Metadata
- Authors
- Stradiotto, E., Allegrini, D., Fossati, G., Raimondi, R., Sorrentino, T., Tripepi, D., Barone, G., Inforzato, A., & Romano, M. R.
- Affiliations
- Humanitas University (IT)
- Humanitas Castelli (IT)
- Corresponding author
- Stradiotto, Elisa
- ORCID
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2022-10-31
- Volume
- 23
- Issue
- 21
- Pages
- 13280
- ISSN
- 1422-0067 (ISSN-L)
- PMC
- PMC9653831
- OpenAlex
- W4308124848
- Cited by
- 29
- References
- 181
- Citations by year
- 2026: 4 · 2025: 6 · 2024: 14 · 2023: 5
- FWCI
- 1.34
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- International Journal of Molecular Sciences (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Topics
- Health Sciences › Medicine › Ophthalmology › Retinal Diseases and Treatments
- Health Sciences › Medicine › Ophthalmology › Retinal Development and Disorders
- Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Retinal Imaging and Analysis
- Keywords
- age-related macular degeneration, genetic polymorphism, genetic risk prediction, polygenic risk score, complement overactivation, gene therapy, anti-VEGF therapy, retinal disease, therapeutic target
- MeSH terms
- Complement System Proteins, Humans, Macular Degeneration, Polymorphism, Genetic, Angiogenesis Inhibitors, Polymorphism, Single Nucleotide
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.